Oslo, 20 January 2017 - Navamedic ASA today announced that the European Patent Office has granted a patent for Sippcoat® to be used in any urine handling system to help prevent bacteria migration. This brings with it significant long term commercial potential for Navamedic.
"We are pleased to have been granted a European patent for Sippcoat, an innovative encapsulated silicone-oil technology for biofilm inhibition in urine drainage devices. The patent is another exciting development for Navamedic and represents an important milestone in the commercialisation of the Sippi product family. The patent means Sippcoat is protected to be used in any urine collection bags, which yields major licensing opportunities and hence an additional multi-million NOK market potential for Navamedic," says Magnus Emmoth, CEO of Navamedic Medtech.
Sippcoat® is a soluble capsule, which incorporates silicone oil in an oil-releasing mechanism. The mechanism is automatically activated by the patient after application, and inhibits biofilm formation inside urine handling systems. Biofilm formation is the root cause for bacterial growth on medical devices, and the silicone oil helps prevent nosocomial infections in urine bags.
"Completed and initiated clinical studies will together enhance a strong body of evidence supporting the bacteria-preventing properties of the innovative Sippcoat-technology," says Magnus Emmoth.
For further information, please contact:
Magnus Emmoth, CEO of Navamedic Medtech
Phone: +46 704 12 11 97
Email: me@navamedic.com
Navamedic ASA is a Norwegian medtech and pharmaceutical products company, delivering products to patients, hospitals and pharmacies in the Nordic and Benelux markets. The Group's Medtech business has developed and is currently introducing the next generation of digital urine meter Sippi®. Navamedic's Pharma and Healthcare business is a distributor of products supplied by a number of pharmaceutical manufacturers. Navamedic is listed on the Oslo Stock Exchange (ticker: NAVA).